|
|
|
|
Vol. 58, Issue 5, 1035-1041, November 2000
Department of Clinical Biochemistry, Bispebjerg Hospital,
Copenhagen, Denmark (J.W.T., J.F.); and Chemistry Department, The Royal
Veterinary and Agricultural University, Copenhagen, Denmark (R.M.J.,
A.H.)
We have used combinatorial chemistry with amino acid mixtures (X) at
positions 6 to 23 in vasoactive intestinal peptide (VIP) to optimize
binding affinity and selectivity to the rat VPAC1 receptor.
The most efficient amino acid replacement was a substitution of alanine
at position 18 to diphenylalanine (Dip), increasing the displacement
efficiency of 125I-VIP by 370-fold. The
[Dip18]VIP(6-23) was subsequently used to find a second
replacement, employing the same approach. Tyrosine at position 9 was
selected and the resulting
[Tyr9,Dip18]VIP(6-23) analog has a
Ki value of 90 nM. This analog was unable to
stimulate cAMP production at 10
6 M but was able to
inhibit VIP-induced cAMP stimulation
(Kb = 79 nM). The
Ki values of
[Tyr9,Dip18]VIP(6-23) using the rat
VPAC2 and PAC1 receptors were 3,000 nM and
>10,000 nM, respectively. Thus,
[Tyr9,Dip18]VIP(6-23) is a selective
VPAC1 receptor antagonist. The C-terminally extended form,
[Tyr9,Dip18]VIP(6-28), displays improved
antagonistic properties having a Ki and
Kb values of 18 nM and 16 nM, respectively.
On the contrary, the fully extended form,
[Tyr9,Dip18]VIP(1-28), was a potent agonist
with improved binding affinity (Ki = 0.11 nM) and ability to stimulate cAMP (EC50 = 0.23 nM) compared with VIP (Ki = 1.7 nM,
EC50 = 1.12 nM). Furthermore, the specificity of this
agonist to the VPAC1 receptor was high, the
Ki values for the VPAC2 and
PAC1 receptors were 53 nM and 3,100 nM, respectively. Seven
other analogs with the [Tyr9,Dip18]
replacement combined with previously published VIP modifications have
been synthesized and described in this work.